Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18074011 | 0.81 | PIK3CD (0.45) | PIK3CDCYP2D6SMN1; SMN2 | |
| SCHEMBL9976596 | 0.81 | PIK3CD (0.45) | PIK3CDCYP2D6SMN1; SMN2 | |
| SCHEMBL18926695 | 0.80 | PIK3CD (0.58) | PIK3CDCYP2D6SMN1; SMN2 | |
| SCHEMBL14752172 | 0.80 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL14752132 | 0.80 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL14752140 | 0.80 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL24841690 | 0.80 | PIK3CD (0.48) | PIK3CD | |
| SCHEMBL25557379 | 0.78 | PIK3CD (0.42) | PIK3CDSMN1; SMN2 | |
| SCHEMBL17471238 | 0.77 | GBA1 (0.35) | PIK3CD | |
| SCHEMBL3418530 | 0.77 | PIK3CD (0.45) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024077023-A2 | CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-9469638-B2 | Substituted polycyclic carbamoylpyridone derivative | SHIONOGI & CO., LTD. (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-09-24 | — | — | US | disclosed |
| US-20150111854-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO (JP) | 2015-04-23 | — | — | US | disclosed |
| US-8987441-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20150065485-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2015-03-05 | — | — | US | disclosed |
| US-8927710-B2 | Substituted polycyclic carbamoylpyridone derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20130197219-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2444400-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111854-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | PIK3CD 1483/4885CYP2D6 939/4885SMN1; SMN2 4304/4885 |
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, WNT1 | PIK3CD 1573/4885CYP2D6 3699/4885SMN1; SMN2 3237/4885 |
| US-20150065485-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | PIK3CD 2508/4885CYP2D6 1683/4885SMN1; SMN2 4520/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | PIK3CD 1678/4885CYP2D6 2910/4885SMN1; SMN2 716/4885 |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | PIK3CD 2508/4885CYP2D6 1683/4885SMN1; SMN2 4520/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885CYP2D6 3599/4885SMN1; SMN2 2647/4885 |
| US-20130197219-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | PIK3CD 1483/4885CYP2D6 939/4885SMN1; SMN2 4304/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | PIK3CD 1645/4885CYP2D6 1271/4885SMN1; SMN2 1711/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885CYP2D6 3599/4885SMN1; SMN2 2647/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885CYP2D6 3599/4885SMN1; SMN2 2647/4885 |
| US-11787800-B2 | BRD9 degraders and uses thereof | BRD9, BRWD1, BRD2 | PIK3CD 1944/4885CYP2D6 3138/4885SMN1; SMN2 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.